Open Access Full Text Article

ORIGINAL RESEARCH

Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis

Yi-Xin Hao^{1,*} Qiang Fu^{2,*} Yan-Yan Guo¹ Ming Ye¹ Hui-Xia Zhao¹ Qi Wang¹ Xiu-Mei Peng¹ Qiu-Wen Li¹ Ru-Liang Wang¹ Wen-Hua Xiao¹

¹Department of Oncology, First Affiliated Hospital, ²Department of Anesthesiology, People's Liberation Army General Hospital, Beijing, People's Republic of China

*These authors contributed equally to this work

Correspondence: Yi-Xin Hao; Wen-Hua Xiao Department of Oncology, First Affiliated Hospital, People's Liberation Army General Hospital, No 51 Fucheng Road, Haidian District, Beijing, People's Republic of China Tel +86 10 6684 8673; +86 10 6684 8671 Email 15901537871@163.com; w_hxiao@hotmail.com



Abstract: Circulating tumor DNA (ctDNA) can be identified in the peripheral blood of patients and harbors the genomic alterations found in tumor tissues, which provides a noninvasive approach for detection of gene mutations. We conducted this meta-analysis to investigate whether ctDNA can be used for monitoring KRAS gene mutations in colorectal cancer (CRC) patients. Medline, Embase, Cochrane Library and Web of Science were searched for the included eligible studies in English, and data were extracted for statistical analysis according to the numbers of true-positive (TP), true-negative (TN), false-positive (FP) and false-negative (FN) cases. Sensitivity, specificity and diagnostic odds ratio (DOR) were calculated, and the area under the receiver operating characteristic curve (AUROC) was used to evaluate the diagnostic performance. After independent searching and reviewing, 21 studies involving 1,812 cancer patients were analyzed. The overall sensitivity, specificity and DOR were 0.67 (95% confidence interval [CI] =0.55-0.78), 0.96 (95% CI =0.93-0.98) and 53.95 (95% CI =26.24-110.92), respectively. The AUROC was 0.95 (95% CI =0.92–0.96), which indicated the high diagnostic accuracy of ctDNA. After stratified analysis, we found the higher diagnostic accuracy in subgroup of patients detected in blood sample of plasma. The ctDNA may be an ideal source for detection of KRAS gene mutations in CRC patients with high specificity and diagnostic value. Keywords: cancer, KRAS, mutation, circulating tumor DNA

Introduction

Cancer is becoming the second most common cause for death in recent years.¹ Surgery is the main treatment for early cancer patients; adjuvant and palliative treatments are mainly used in patients with advanced cancer, involving traditional chemotherapy and targeted therapy. Pathological test of tumor tissues is the gold standard method for histological diagnosing, and detection of gene mutations in tumor tissues is a directive factor for selection of targeted drugs.² For non-small cell lung cancer (NSCLC), the status of EGFR gene mutations is a sensitive and reliable biomarker for EGFR-TKIs therapy (eg, gefitinib and erlotinib).^{3,4} For colorectal cancer (CRC), the anti-EGFR MoAb (eg, cetuximab) is now restricted to patients with wild-type KRAS gene, and the mutation status of BRAF gene is predictive of the drug resistance of anti-EGFR MoAb in wild-type KRAS patients.^{5,6} At the same time, detection of other gene mutations has also been used in patients with different cancers. For diagnosing genomic mutation, biopsy and surgery of primary and metastatic tumors are the main resources of tumor tissues, but they are invasive, uncomfortable and of high cost.^{7,8} Thus, new non-invasive methods for gene detection are increasingly focused on.

OncoTargets and Therapy 2017:10 945-953

OncoTargets and Therapy downloaded from https://www.dovepress.com/

© 2017 Hao et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, lates ese paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).

945

Circulating tumor DNA (ctDNA) is tumor DNA of cell-free DNA (cfDNA) circulating in plasma or serum of cancer patients,⁹ which is ~170 bp. ctDNA originates from tumor cells, which can be identified in blood samples, and rapidly disappears after surgery or chemotherapy. The level of ctDNA is significantly higher in cancer patients than in healthy controls, which can harbor the somatic genomic alterations found in tumor tissues.^{10,11} Unlike tissue biopsy, obtaining a sample of ctDNA is a noninvasive approach, with less risk and lower cost. Thus, detection of ctDNA is actively being explored and provides opportunities for minimally invasive cancer diagnosis, prognosis and tumor monitoring

Many studies have been carried out to validate the possibility of ctDNA as a new source for detection of gene mutations. On the basis of this background, we decided to conduct this meta-analysis to investigate the diagnostic value of ctDNA for detection of KRAS gene mutations in CRC patients. The results will help establishing whether ctDNA can be used for detection of gene mutations in cancer patients.

Materials and methods Literature search strategy

in cancer patients.12-15

Two investigators independently searched Medline, Embase, Cochrane library and Web of Science databases for potentially relevant articles between inception and January 31, 2016. The search heading terms and keywords were "carcinoma" or "cancer" or "neoplasm", "serum" or "plasma" or "circulating", "KRAS" and "mutation", which were limited to English publications in human beings. Then, the results were manually searched for included studies and doublechecked by a second investigator.

Selection criteria

We searched the full-text articles that investigated the comparison of detection of KRAS gene mutations between tumor tissue and the matched plasma or serum in CRC patients. The following publications were excluded: abstracts, news, letters, case reports and reviews. Publications retrieved from databases were first screened by titles and abstracts; full-text articles were reviewed and selected according to the inclusion criteria. The inclusion criteria were as follows: 1) CRC patients should be diagnosed by histopathological or cytological examination; 2) KRAS mutations should be detected in tumor tissue and the paired ctDNA; 3) sufficient information should be provided to conduct the statistical analysis; and 4) studies should be limited to human trials and published in English language. The study with most patients was included from those reported using the same technique by the same center.

Data extraction and quality assessment

Two investigators independently abstracted following information from each trial: name of the first author, year of publication, location where the study was performed, number of patients enrolled, stage of cancer (according to tumor-node-metastasis [TNM] criteria), storage method of tumor tissues, detection method of ctDNA, collection time of blood samples (before or after chemotherapy), format of blood samples (serum or plasma), true positive (TP), false negative (FN), false positive (FP) and true negative (TN). When the study included ≥ 2 methods of mutation detection, we used the data with the best sensitivity or specificity. The discrepancy between the 2 investigators was resolved by discussion among all the authors. Quality assessment of eligible studies was evaluated using QUADAS-2 (quality assessment of studies of diagnostic accuracy included in systematic reviews-2).

Statistical analysis

The publication bias was detected using Deeks funnel plot, and P < 0.05 suggested the significant publication bias. The detection of KRAS gene mutation in tumor tissues acted as the gold standard for diagnosing gene mutation in this analysis. We calculated the sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), corresponding 95% confidence intervals (95% CIs) and area under the ROC curve (AUROC), according to the numbers of TP, TN, FP and FN. Subgroup analyses were also conducted according to different clinical data. Statistical heterogeneity was evaluated by Q test and inconsistency index (I^2), with significant heterogeneity set at $P \le 0.05$ and $I^2 > 50\%$. All statistical analyses were performed using STATA software (version 12.1, StataCorp LP) with the Midas module.

Results Eligible studies

After independent searching, 6,033 records were retrieved from these databases. After reviewing the titles and abstracts, 5,977 records were excluded. After full-text articles were reviewed, 20 publications were considered to be eligible for inclusion in our analysis (Figure 1).^{15–34} In the article reported by Morgan et al,²⁵ the blood samples including serum and plasma were analyzed. Subsequently, 21 eligible studies



Figure I A flow chart showing the studies included in this meta-analysis.

were included for analyzing the effectiveness of ctDNA for detection of KRAS gene mutations in CRC patients.

Study characteristics

Our analysis included 21 eligible studies, which are shown in Table 1. In total, 5 studies were from China, 4 from France, 3 from the USA, 2 from Italy, 2 from Japan, 1 from Switzerland, 1 from multi-country, 1 from Denmark, 1 from Korea and 1 from the Netherlands. A total of 1,812 CRC patients were included. In all, 18 studies detected both codon 12 and codon 13 of KRAS gene. A total of 3 studies detected only codon 12 of KRAS gene. In all, 14 studies reported the exact collection times of both tumor tissue samples and blood samples, which were collected before chemotherapy. A total of 16 circulating blood samples were plasma and 5 samples were serum. In all, 12 formalinfixed and paraffin-embedded (FFPE) tumor tissue samples were used for detection of KRAS gene mutations; 4 tumor tissues were frozen before detection. Various detection methods were used, in which the allele refractory mutation system - quantitative polymerase chain reaction (ARMSqPCR) was the most frequently reported.

Study quality

We assessed the quality of eligible studies by QUADAS-2 and found that the quality of all studies was good (Table 2). The Deeks regression test was performed, and no significant publication bias was detected (P=0.060; Figure 2).

Meta-analysis of specificity and sensitivity in overall population

In our analysis, the overall pooled specificity was 0.96 (95% CI =0.93-0.98), the pooled sensitivity was 0.67 (95% CI =0.55–0.78), the DOR was 53.95 (95% CI =26.24–110.92) and the AUROC was 0.95 (95% CI =0.92-0.96) (Figure 3 and Table 3). Specificity can quantify the ability of avoiding FPs, so the high specificity indicated high accuracy of ctDNA for detection of KRAS gene mutations. Sensitivity refers to the ability of correctly detecting patients who do have the condition. Considering the trade-off between sensitivity and specificity, AUROC is used to measure the diagnostic performance of ctDNA. When AUROC is >0.9, the diagnostic accuracy is high enough for a detection method to act as an effective maker. The PLR was 18.33 (>10), suggesting that it could be used for confirming KRAS gene mutations. The NLR was 0.34 (>0.1), showing that a negative result was 34% likely to be an FN (Figure 4 and Table 3). The between-study heterogeneity was evaluated by chi-square test (Q = 53.58, P = 0.000 < 0.05) and I-square test (I²=96.27, 95% CI =93.48-99.06), which suggested the significantly high heterogeneity. From the likelihood ratio (LR) scattergram, we found that ctDNA was located in the right upper quadrant, indicating ctDNA could be used for confirming KRAS gene mutations (Figure 5).

Subgroup analysis

To determine the effect of potential confounding factors, we performed subgroup analyses measured by AUROC and

	Z				Mathod		Sancitivity	Shorifinity		Z	۵ u	Z
		Discus					Contraction of	operiment	:		:	
i 206	Advanced	AA	Plasma	NA	dPCR	12, 13	0.872	0.992	68	0	_	127
85	>⊢I	Frozen	Plasma	Before	ARMS-qPCR	12, 13	0.815	0.931	22	ъ	4	5
2a 65	Advanced	FFPE	Serum	NA	RFLP-PCR	12, 13	0.581	0.765	8	13	8	26
135	NA	FFPE	Plasma	Before	RFLP-PCR	12	0.829	0.930	29	9	7	93
a 52	>I-I<	NA	Plasma	NA	PNA-PCR	12, 13	000.1	0.703	15	0	=	26
се 24	≥	AA	Serum	NA	Real-time PCR	12, 13	0.500	1.000	7	7	0	0
a 133	>I-I<	Frozen	Plasma	Before	MassARRAY	12, 13	0.456	1.000	41	49	0	43
a 62	NA	Frozen	Plasma	Before	Nested cold-PCR	12	0.750	0.920	6	č	4	46
1 42	>I-I	FFPE	Plasma	Before	PNA-PCR	12, 13	0.615	0.931	œ	ъ	7	27
71	≥	FFPE	Plasma	Before	ARMS-qPCR	12, 13	0.313	0.949	0	22	2	37
71	≥	FFPE	Serum	Before	ARMS-qPCR	12, 13	0.281	1.000	6	23	0	39
zerland I4	NA	NA	Plasma	Before	MASA-PCR	12	0.857	1.000	9	_	0	7
12	NA	FFPE	Plasma	Before	ME-PCR	12, 13	0.000	1.000	0	ъ	0	7
a 115	>I-I	FFPE	Serum	Before	Nested PCR	12, 13	0.243	0.949	6	28	4	74
Vetherlands 78	>I-I<	FFPE	Serum	Before	ME-PCR	12, 13	0.756	0.973	ЗІ	0	_	36
۱5 I	NA	FFPE	Plasma	NA	NGS	12, 13	0.714	1.000	2	2	0	œ
ce 34	≥	FFPE	Plasma	Before	dPCR	12, 13	0.688	1.000	=	S	0	8
mark 211	≥	FFPE	Plasma	Before	ARMS-qPCR	12, 13	0.800	0.958	112	28	m	68
се 50	≥	Frozen	Plasma	NA	qPCR	12, 13	0.789	0.935	15	4	7	29
се 95	≥	AA	Plasma	NA	APCR	12, 13	0.923	0.982	36	m	_	55
a 242	≥	FFPE	Plasma	Before	PNA-PCR	12, 13	0.547	0.904	64	53	12	113
tastasis; TP, true positive; F ^T ⁻ PE, formalin-fixed and paraff ⁰ CR, mutant specific alleles –	 A, false negative; FF in-embedded; RFLF polymerase chain r 	, false positiv -PCR, restric -eaction; ME-	ve; TN, trué ction fragme PCR, mutar	e negative; NA, na int length polymo it-enriched polym	ot applicable; dPCR, digi rphism – polymerase cha ierase chain reaction, NK	tal polymeras iin reaction; P GS, next-gene	e chain reaction; NA-PCR, peptide sration sequencing	ARMS-qPCR, allel nucleic acid-medi ; qPCR, quantitati	e refract ated poly ive polym	ory muta merase c ierase ch	ttion syst chain rea ain react	tem – ction; tion.
	a 65 a 52 b 52 c 24 a 135 c 24 a 133 a 62 a 133 a 62 a 13 a 133 a 24 a 133 a 133 a 24 a 133 a 24 a 12 a 15 e 34 a 115 e 34 a 211 e 50 e 51 a 24 a 133 a 24 a 12 a 115 a 115 a 24 a 21 a 21 a 24 a 21 a 24 a 2 a 2 a 2 a 2 a 2 a 2 a 2 a 2	a 65 Advanced a 52 Advanced a 52 NA a 52 NA a 52 NA a 52 NA a 62 NA a 62 NA a 133 LHV 71 IV 71 IV 71 IV 8 NA 71 NA 8 NA 71 NA 8 NA 7 NA 7 NA 7 NA 8 NA 7 NA 7 NA 7 NA 7 NA 7 NA 7 NA 7 NA 8 NA 7 NA 7 NA 8 NA 7 NA 7 NA 7 NA 8 NA 7 NA 8 NA 7 NA 8 NA 7 NA 7 NA 8 NA 7 NA 8 NA 7 NA 7 NA 7 NA 8 NA 7 NA 7 NA 8 NA 7 NA 7 NA 8 NA 7 NA 8 NA 7 NA 8 NA 7 NA 8 NA 7 NA 8 NA 8 NA 7 NA 8	a 65 Advanced FFPE a 52 I-IV NA 52 I-IV NA 52 I-IV NA 52 I-IV NA 52 I-IV NA 53 I-IV Frozen 42 I-IV FFPE 71 IV FFPE 71 IV FFPE 71 IV FFPE 6 12 NA FFPE 71 IV FFPE 6 14 NA NA 71 IV FFPE 6 34 IV FFPE 6 34 IV FFPE 6 34 IV FFPE 6 34 IV FFPE 8 1-IV FFPE 8 1-IV FFPE 9 1-IV FFPE 8 1-IV FFPE 9 1-IV FFPE 8 1-IV FFPE 9 1-IV FFPE 8 1-IV FFPE 9 1-IV FFFE 9 1-IV FFFE	a 65 Advanced FFPE Serum a 52 HJV NA FFPE Plasma b 52 HJV NA Plasma c 24 IV NA Serum a 62 NA Frozen Plasma a 62 NA Frozen Plasma 71 IV FFPE Plasma 8 HJV FFPE Plasma 8 HJV FFPE Plasma 8 HJV FFPE Plasma 9 III II V FFPE Plasma 8 HJV FFPE Plasma 9 III N FFPE Plasma 9 III N FFPE Plasma 9 III N FFPE Plasma 1 II N FFPE Plasma 1 II N FFPE Plasma 1 II N FFPE Plasma 1 II N FFPE Plasma 8 A 10 FFPE Plasma 1 II N FFPE Plasma 8 A 10 FFPE Plasma 9 A 10 FFPE Plasma 1 II N FFPE Plasma 1 II N FFPE Plasma 1 II N FFPE Plasma 8 A 10 FFPE Plasma 1 II N FFPE Plasma 8 A 10 FFPE Plasma 8 A 10 FFPE Plasma 1 II N FFPE Plasma 8 A 10 FFPE Plasma 1 II N FFPE Plasma 8 A 10 FFPE Plasma 8 A 10 FFPE Plasma 8 A 10 FFPE Plasma 8 A 10 FFPE Plasma 1 II N FFPE Plasma 8 A 10 FFPE Plasma 1 II N FFPE Plasma 8 A 10 FFFE Plasma 8 A 10 FFFE Plasma 8 A 10 FFFE Pl	a 65 Advanced FFPE Serum NA 135 NA FFPE Plasma Before 24 IV NA Plasma NA 2 24 IV NA Serum NA 2 24 IV NA Serum NA 2 24 IV NA Serum Before 2 24 IV FFPE Plasma Before 2 24 IV FFPE Plasma Before 7 1 IV FFPE Plasma Before 7 1 IV FFPE Plasma Before 6 12 NA FFPE Plasma Before 1 12 NA FFPE Plasma Before 8 115 I-1V FFPE Plasma Before 1 12 NA FFFE Plasma Before 1 12 NA FFPE Plasma Before 1 12 NA FFPE Plasma Before 1 12 NA FFPE Plasma	a 65 Advanced FFPE Serum NA RFLP-PCR a 52 I-IV NA Plasma Before RFLP-PCR a 52 I-IV NA Plasma NA PNA-PCR a 52 I-IV NA Serum NA Real-time PCR a 62 NA Frozen Plasma Before MassARRAY a 62 NA Frozen Plasma Before MassARRAY 71 IV FFPE Plasma Before Nested cold-PCR 71 IV FFPE Plasma Before MAS-qPCR 71 IV FFPE Plasma Before MAS-qPCR 71 IV FFPE Plasma Before PNA-PCR 71 IV FFPE Serum Before MAS-qPCR 12 NA FFPE Plasma Before MCS-qPCR 12 NA FFPE Plasma Before MCS-qPCR 12 NA FFPE Plasma Before MCS-qPCR 13 I-IV FFPE Serum Before MCS-qPCR 14 II5 I-IV FFPE Serum Before MCS-qPCR 15 NA FFPE Plasma Before MCS-qPCR 16 I-IV FFPE Serum Before MCS-qPCR 17 IV FFPE Serum Before MCS-qPCR 18 I-IV FFPE Plasma Before MCS-qPCR 19 I-IV FFPE Serum Before MCS-qPCR 10 I-IS I-IV FFPE Plasma Refore MCS-qPCR 10 I-IS I-IV FFPE Plasma Before MCS-qPCR 11 II5 I-IV FFPE Plasma Before MCS-qPCR 12 I-IV FFPE Plasma Before MCS-qPCR 14 I-IV FFPE Plasma Refore MCS-qPCR 15 NA FFPE Plasma Refore MCS-qPCR 16 FFPE Plasma Refore MCS-qPCR 17 242 IV FFPE Plasma Refore ARMS-qPCR 18 FFFE Plasma Refore ARMS-qPCR 19 C Frozen Plasma NA QPCR 10 Z-11 IV FFPE Plasma Refore PNA-PCR 24 IV NA PLA-PCR, restriction fragment length polymorphism - polymerase chain reaction, NE-PCR, mutant-specific alleles - polymerase chain reaction, NE-PCR, mutant-specific alleles - polymerase chain reaction, NE-PCR, mutant specific alleles - polymerase chain reaction, ME-PCR, mutant specific alleles - polymerase chain reaction, ME-PCR, mutant specific alleles - polymerase chain reacti	a 65 Advanced FPE Serum NA RFLP-PCR 12, 13 135 NA FFPE Serum NA RFLP-PCR 12, 13 252 LIV NA Plasma Before RFLP-PCR 12, 13 253 LIV NA Serum NA Real-time PCR 12, 13 254 IV NA Serum NA Real-time PCR 12, 13 255 LIV Frozen Plasma Before MassARRAY 12, 13 256 NA Frozen Plasma Before MassARRAY 12, 13 251 LIV FFPE Plasma Before Nested cold-PCR 12, 13 251 LIV FFPE Plasma Before ARNS-PFCR 12, 13 251 LIV FFPE Plasma Before ARNS-PFCR 12, 13 251 LIV FFPE Plasma Before ARNS-PFCR 12, 13 251 LIV FFPE Plasma Before MassARRAY 12, 13 251 LIV FFPE Plasma Before ARNS-PFCR 12, 13 251 LIV FFPE Plasma Before ARNS-PFCR 12, 13 251 LIV FFPE Plasma Before ME-PCR 12, 13 251 LIV FFPE Plasma Before ME-PCR 12, 13 251 LIV FFPE Plasma Before ME-PCR 12, 13 252 LIV FFPE Plasma Before ME-PCR 12, 13 253 LI LIV FFPE Plasma Before ME-PCR 12, 13 253 LI LIV FFPE Plasma Before ME-PCR 12, 13 265 LIV RFPE Plasma NA 10GS 12, 13 265 LIV RFPE Plasma CVA 102 Plasma Plasma Plasma CVA, 64 PCR, 44 plasma Plasma Plasma CVA, 64 PCR, 44 plasma Plasma Plasma Plasma CVA, 64 PCR, 44 plasma Plasma Plasma CVA, 64 plasma Plasma CVA, 64 plasma Plasma CVA, 64 plasma Plasma CVA, 64 plasma Plasma Plasma CVA, 64 plasma Plasma CVA, 64 plasma Plasma Plasma CVA, 64 plasma Plasma Plasma CVA, 64 plasma Pl	a b3 HV Fraction Fraction	a 65 Advanced FTPE Flam Before Anvis-arch 12,13 0.013 0.033 0.033 0.033 0.033 0.033 0.033 0.033 0.035 <th< td=""><td>0 1/V FTPE Serum NA FRLP-PCR 1,1 0.013 0.033<td>03 HV FTOZEN NAM RELPCR 12,13 0.013 0.031</td><td>0 1W FTPE Serum NA FRP-PCR 12.1 3 0.55 13 13 8 13 8 13 8 13 8 13 8 13 14 17 10 0 13 15 0 11 ie 13 I-IV NA Ren PRAFCR 12.1 0.050 13 0 14 14 9 0 11 ie 62 NA Refore NASAFCR 12.1 0.455 10 12 1 14 9 0 12 2 2 2 2 2 1 10 12 2 1 10 12 2 1 10</td></td></th<>	0 1/V FTPE Serum NA FRLP-PCR 1,1 0.013 0.033 <td>03 HV FTOZEN NAM RELPCR 12,13 0.013 0.031</td> <td>0 1W FTPE Serum NA FRP-PCR 12.1 3 0.55 13 13 8 13 8 13 8 13 8 13 8 13 14 17 10 0 13 15 0 11 ie 13 I-IV NA Ren PRAFCR 12.1 0.050 13 0 14 14 9 0 11 ie 62 NA Refore NASAFCR 12.1 0.455 10 12 1 14 9 0 12 2 2 2 2 2 1 10 12 2 1 10 12 2 1 10</td>	03 HV FTOZEN NAM RELPCR 12,13 0.013 0.031	0 1W FTPE Serum NA FRP-PCR 12.1 3 0.55 13 13 8 13 8 13 8 13 8 13 8 13 14 17 10 0 13 15 0 11 ie 13 I-IV NA Ren PRAFCR 12.1 0.050 13 0 14 14 9 0 11 ie 62 NA Refore NASAFCR 12.1 0.455 10 12 1 14 9 0 12 2 2 2 2 2 1 10 12 2 1 10 12 2 1 10

Table I Characteristics of eligible studies

First author	Risk of bias			Application concerns			
	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard
Bettegowda et al ¹⁶	L	U	U	L	L	L	L
Danese et al ¹⁷	L	U	U	L	L	L	L
Kim et al ¹⁸	L	U	U	L	L	L	L
Kopreski et al ¹⁹	L	U	U	L	L	L	L
Kuo et al ²⁰	L	U	U	L	L	L	L
Lefebure et al ²¹	L	U	U	L	L	L	L
Lin et al ²²	L	L	L	L	L	L	L
Liu et al ²³	L	U	U	L	L	L	L
Miyano et al ²⁴	L	U	U	L	L	L	L
Morgan et al ²⁵	L	L	L	L	L	L	L
Morgan et al ²⁵	L	L	L	L	L	L	L
Mulcahy et al ²⁶	L	U	U	L	L	L	L
Perrone et al ²⁷	L	U	U	L	L	L	L
Pu et al ²⁸	L	U	U	L	L	L	L
Ryan et al ²⁹	L	U	U	L	L	L	L
Sakai et al ³⁰	L	U	U	L	L	L	L
Sefrioui et al ³¹	L	н	L	L	L	L	L
Spindler et al ³²	L	L	L	L	L	L	L
Taly et al ³³	L	U	U	L	L	L	L
Thierry et al ¹⁵	L	U	U	L	L	L	L
Xu et al ³⁴	L	L	L	L	L	L	L

Table 2 QUADAS-2 score of eligible studies

Abbreviations: L, low; U, unclear; H, high; QUADAS-2, quality assessment of studies of diagnostic accuracy included in systematic reviews-2.

stratified according to TNM stage, storage method of tumor tissues, blood sample format, ctDNA detection method and detection site of KRAS gene mutation (Table 3). For blood samples, the AUROC was higher in plasma (0.96, 95% CI =0.94–0.97) than in serum (0.83, 95% CI =0.79–0.86), indicating the higher diagnostic accuracy (P=0.000<0.05). With regard to detection methods, ARMS-qPCR was the most frequently used (0.96, 95% CI =0.94–0.97). However,



Figure 2 The Deeks regression line showing the publication bias of studies. Abbreviations: ESS, effective sample size; DOR, diagnostic odds ratio. there was no statistically significant difference in diagnostic accuracy between different cancer stages, storage methods of tumor tissues, ctDNA detection method and detection site of KRAS gene mutation.

SROC with confidence and predictive ellipses



Figure 3 The SROC curve of ctDNA for detection of KRAS gene mutations. Abbreviations: SROC, summary receiver operating characteristic; AUC, area under the curve.

Table 3 Meta-analysis of subgroup

Subgroup analyses	n	Sensitivity	Specificity	AUROC	DOR	PLR	NLR
All	21	0.67 (0.55–0.78)	0.96 (0.93-0.98)	0.95 (0.92-0.96)	53.95 (26.24–110.92)	18.33 (10.14–33.16)	0.34 (0.24-0.49)
TNM stage							
Advanced	10	0.66 (0.50-0.79)	0.97 (0.93–0.99)	0.95 (0.93–0.97)	71.52 (21.18–241.57)	24.88 (9.36-66.17)	0.35 (0.22-0.54)
I–IV	6	0.73 (0.40-0.92)	0.93 (0.86–0.97)	0.94 (0.92–0.96)	37.80 (14.18–100.79)	11.02 (6.18–19.66)	0.29 (0.11–0.77)
Storage of tissue							
FFPE	12	0.55 (0.40-0.69)	0.96 (0.92-0.98)	0.93 (0.90-0.95)	29.19 (12.47–68.33)	13.63 (6.88–27.01)	0.47 (0.34-0.65)
Frozen	4	0.70 (0.51–0.84)	0.95 (0.88–0.98)	0.94 (0.91–0.96)	48.17 (18.44–125.87)	15.07 (6.29–36.09)	0.31 (0.18-0.54)
Format of blood							
Plasma	16	0.74 (0.60–0.84)	0.97 (0.93–0.98)	0.96 (0.94–0.97)	77.45 (39.03–153.72)	20.93 (11.58–37.82)	0.27 (0.17-0.43)
Serum	5	0.47 (0.29–0.66)	0.96 (0.84–0.99)	0.83 (0.79–0.86)	22.16 (4.30–114.30)	12.25 (2.69–55.84)	0.55 (0.39-0.79)
Detection method							
ARMS-qPCR	4	0.58 (0.30-0.81)	0.96 (0.91–0.98)	0.96 (0.94–0.97)	34.90 (11.17–109.07)	15.38 (6.96–34.01)	0.44 (0.23-0.85)
Detection site							
Codon 12	21	0.67 (0.55–0.78)	0.96 (0.93–0.98)	0.95 (0.92–0.96)	53.95 (26.24–110.92)	18.33 (10.14–33.16)	0.34 (0.24–0.49)
Codon 12, 13	18	0.65 (0.50-0.77)	0.97 (0.93–0.99)	0.95 (0.92–0.96)	55.56 (23.97–128.81)	20.26 (9.97–41.18)	0.37 (0.25–0.54)

Note: Data presented as n (95% confidence interval).

Abbreviations: AUROC, area under the ROC curve; DOR, diagnostic odds ratio; PLR, positive likelihood ratio; NLR, negative likelihood ratio; TNM, tumor-nodemetastasis; FFPE, formalin-fixed and paraffin-embedded; ARMS-qPCR, allele refractory mutation system - quantitative polymerase chain reaction.





Figure 5 LR scattergram of ctDNA for detection of KRAS gene mutations. **Abbreviations:** LR, likelihood ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio; CI, confidence interval; LUQ, left upper quadrant; LRP, likelihood ratio for positive results; RUQ, right upper quadrant; LLQ, left lower quadrant; RLQ, right lower quadrant; LRN, likelihood ratio for negative results.

Figure 4 Fagan's nomogram of ctDNA for detection of KRAS gene mutations. **Abbreviation:** LR, likelihood ratio.

Discussion

Cancer is the main cause of death, and effective treatment can significantly reduce the mortality of patients with carcinoma. Besides the traditional chemotherapy based on pathological diagnosis, targeted therapy has been widely used according to gene mutation status. Gene evaluation of tumor tissue is the gold standard for assessing mutation status, but it is usually carried out only once because of the invasiveness and costliness. However, genomic alterations may vary in primary and metastatic tumor tissues with the progression of cancer, which need the repetitive genotyping.

As we know, cancer generation and progression are associated with numerous genetic and epigenetic factors, some of which can be detected in gene alternations of tumor tissues. ctDNA, also known as part of cfDNA, can be released into blood and other body fluids from tumor tissues, carrying tumor-related genetic and epigenetic alterations, and can be more informative, specific and accurate than protein biomarkers. Several observations not only suggested the role of DNA in heredity but also provided the evidence for the occurrence of DNA beyond the confinement of cells. In 1977, Leon et al⁹ reported that the level of cfDNA in the peripheral blood of cancer patients was notably higher than that in healthy controls, especially in those patients with metastatic sites, and significantly reduced after radiation. In 1994, Sorenson et al³⁵ and Vasioukhin et al³⁶ found that RAS gene mutations can be detected in blood cfDNA. As newly improved methods, the detection rate of ctDNA for KRAS and BRAF gene mutations in blood of CRC patients has also been reported in different studies. In 2014, Thierry et al15 reported that ctDNA showed 98% specificity and 92% sensitivity of KRAS gene mutations and 100% specificity and sensitivity of BRAF gene mutations. Kuo et al²⁰ pointed out that the detection rate of cfDNA for KRAS gene mutations in plasma was higher (50%) than in primary tumor tissues (28.8%). However, Perrone et al²⁷ revealed that the KRAS gene mutation rate of cfDNA in plasma was very low (3%) compared to the matched adenocarcinoma tissues (45%). Inconsistent results made the use of ctDNA screening to be unclear. In 2015, Qiu et al¹⁴ compared the diagnostic value of ctDNA for detection of EGFR gene mutations with tumor tissues by a meta-analysis and suggested ctDNA as a highly specific but relatively low-sensitive biomarker in NSCLC patients. In spite of these findings, the clinical utilization of ctDNA for therapeutic monitoring is not yet widespread because of the different results in different studies. Now, we conducted this meta-analysis to suppose the consistency of KRAS gene mutations between ctDNA and the matched tumor tissues in CRC patients, for assessing the possibility of ctDNA used for gene monitoring.

As we know, anti-EGFR MoAb is now restricted to the patients with wild-type KRAS gene.5 Thus, detection of KRAS gene mutations in CRC patients has become a routine clinical test. Now, we analyzed the diagnostic performance of ctDNA for detection of KRAS gene mutations in CRC patients through meta-analysis in order to assess the clinical value of ctDNA detection. In our meta-analysis, publication bias was assessed by a regression of diagnostic log odds ratio against the inverse of the square root of the effective sample size,³⁷ and P=0.060 for the slope coefficient indicated the absence of publication bias and the accuracy of meta-analysis. Our analysis showed that the overall pooled specificity was 96% and the pooled sensitivity was 67%, which were almost as same as what had been reported for ctDNA for detection of EGFR gene mutations (specificity 96%, sensitivity 62%).¹⁴ According to the guideline of AUROC and DOR,³⁸ ctDNA detection of KRAS gene mutations also had high diagnostic accuracy and discriminatory value in CRC patients. LR is also used for evaluating diagnostic accuracy and clinical utility of diagnostic test.37 On basis of the results of PLR and NLR in our analysis, ctDNA was located in the right upper quadrant, indicating that it could be served as a test for confirmation of KRAS gene mutations in CRC patients.

In consideration of the influences of confounding factors on diagnostic accuracy, subgroup analyses were conducted on basis of some common covariates. Many studies have reported that the level of ctDNA was associated with tumor burden and stage.^{22,39,40} ctDNA has also been reported with a higher diagnostic value for detection of EGFR gene mutations in patients with advanced stage of NSCLC.14 However, we did not find any significant diagnostic difference for detection of KRAS gene mutation in different stages of CRC patients, which may be due to insufficient data of I-IV stages. The mechanism of release of ctDNAg from tumor cells is not clear, so the level of ctDNA in peripheral blood may not be in accordance with the TNM stage of cancer. That is to say, ctDNA may be useful for CRC patients in different stages. We also did not find the diagnostic accuracy difference of ctDNA between different detection sites of KRAS gene mutation, while may be for the relatively few studies and low mutation rate of codon 13 in CRC patients. In general, ctDNA is obtained from plasma or serum; FFPE or frozen tumor tissue is usually used. Our further stratified analysis indicated that the detection of ctDNA extracted from plasma was more accurate than that from serum, which was consistent with what had been reported in other studies.¹⁴ In 2015,

Qiu et al pointed out that ctDNA extracted from plasma had higher diagnostic accuracy than that from serum for detection of EGFR gene mutations in NSCLC patients.14 Though FFPE may influence the nucleic acids, we still did not find any significant diagnostic accuracy difference of AUROC between FFPE and frozen tumor tissues. What is more, ARMS-qPCR was the most frequently used and had also been proved with high diagnostic performance. The limitations of our meta-analysis were also discussed to reveal the misinterpretation of present results. First, the relatively small size and potentially important differences in subgroup studies may result in statistical biases. Second, our analysis showed high heterogeneity, but none of the present characteristics could declare the heterogeneity. Because of the insufficient reporting of included studies, we could not analyze the probable influence of some potential factors, eg, ethnicity, pathological diagnosis of carcinoma, collection time of blood, chemotherapy situation and the detailed tumor stage, which might be the main sources of heterogeneity. Third, we did not find any significant difference in diagnostic accuracy for KRAS gene mutations after stratified analyses according to cancer stage and the storage method of tumor tissues. These results were in consonance with those studies of ctDNA for detection of other gene mutations, which could be by reason of the relatively few studies and the unclear records in details. Further studies are still needed to account for these issues.

This meta-analysis revealed that ctDNA detection might be useful for repetitive and noninvasive genotyping of KRAS gene mutations in patients with carcinoma, especially for those patients without the opportunity of biopsy at the decision-making points of treatment. This would be an ideal method of gene detection, particularly for cancer patients who are resistant or unable to catch tumor tissues.

Conclusion

ctDNA may help providing information of diagnostic screen, personalized medicine selection and real-time monitoring for cancer patients.

Acknowledgments

This study was supported by the funding from First Affiliated Hospital of Chinese People's Liberation Army General Hospital. We would like to thank Doctor Jianhua Zhu, Doctor Guanghui Li and Doctor He Zhang for their help and support in study work.

Disclosure

952

The authors report no conflicts of interest in this work.

References

- Centers of Diseases Control and Prevention. Health Status and Determinants. Life Expectancy and Mortality. 2015. Available from: http:// www.cdc.gov/nchs/data/hus/hus15.pdf#019. Accessed May 1, 2016.
- 2. National Comprehensive Cancer Network [webpage on the Internet]. *Guidelines for Detection, Prevention, & Risk Reduction.* 2017. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines. asp. Accessed December 24, 2016.
- Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(31):5034–5042.
- Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer*. 2007;7(3): 169–181.
- Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. *Lancet Oncology*. 2005;6(5):279–286.
- Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med.* 2008;359(17):1757–1765.
- Hol L, de Jonge V, van Leerdam ME, et al. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. *Eur J Cancer*. 2010;46(11):2059–2066.
- Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med.* 2012;366(10):883–892.
- Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Res.* 1977;37(3): 646–650.
- Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. *Cancer Metastasis Rev.* 1999;18(1):65–73.
- 11. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. *Mutat Res.* 2007;635(2–3):105–117.
- Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ, Hoon DS. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. *Cancer Res.* 2006; 66(12):6111–6117.
- Mori T, O'Day SJ, Umatani N, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. *J Clin Oncol.* 2005;23(36):9351–9358.
- Qiu M, Wang J, Xu Y, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a metaanalysis. *Cancer Epidemiol Biomarkers Prev.* 2015;24(1):206–212.
- Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. *Nat Med.* 2014;20(4):430–435.
- Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med.* 2014;6(224):224ra24.
- 17. Danese E, Minicozzi AM, Benati M, et al. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. *PLoS One*. 2015;10(5):e0126417.
- Kim ST, Chang WJ, Jin L, Sung JS, Choi YJ, Kim YH. Can serum be used for analyzing the KRAS mutation status in patients with advanced colorectal cancer? *Cancer Res Treat*. 2015;47(4):796–803.
- Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. *J Natl Cancer Inst.* 2000; 92(11):918–923.
- Kuo YB, Chen JS, Fan CW, Li YS, Chan EC. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. *Clin Chim Acta*. 2014;433:284–289.

- Lefebure B, Charbonnier F, Di Fiore F, et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. *Ann Surg*, 2010;251(2):275–280.
- 22. Lin JK, Lin PC, Lin CH, et al. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. *Ann Surg Oncol.* 2014;21(suppl 4):S680–S686.
- Liu P, Liang H, Xue L, et al. Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/Taq-Man(®) -MGB probe genotyping method. *Exp Ther Med.* 2012;4(1): 109–112.
- Miyano S, Hanazawa K, Kitabatake T, Fujisawa M, Kojima K. Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR. *Exp Ther Med.* 2012;4(5):790–794.
- 25. Morgan SR, Whiteley J, Donald E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. *Clin Med Insights Pathol.* 2012;5:15–22.
- Mulcahy HE, Lyautey J, Lederrey C, et al. Plasma DNA K-ras mutations in patients with gastrointestinal malignancies. *Ann N Y Acad Sci.* 2000; 906:25–28.
- Perrone F, Lampis A, Bertan C, et al. Circulating free DNA in a screening program for early colorectal cancer detection. *Tumori*. 2014; 100(2):115–121.
- Pu X, Pan Z, Huang Y, et al. Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: biological and clinical implications. *Oncol Lett.* 2013;5(1):249–254.
- Ryan BM, Lefort F, McManus R, et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. *Gut.* 2003; 52(1):101–108.
- Sakai K, Tsurutani J, Yamanaka T, et al. Extended RAS and BRAF mutation analysis using next-generation sequencing. *PLoS One*. 2015; 10(5):e0121891.

- Sefrioui D, Sarafan-Vasseur N, Beaussire L, et al. Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. *Dig Liver Dis.* 2015;47(10):884–890.
- Spindler KL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. *PLoS One.* 2015;10(4):e0108247.
- Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. *Clin Chem*. 2013;59(12):1722–1731.
- 34. Xu JM, Liu XJ, Ge FJ, et al. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. *J Exp Clin Cancer Res.* 2014;33:104.
- Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. *Cancer Epidemiol Biomarkers Prev.* 1994;3(1): 67–71.
- Vasioukhin V, Anker P, Maurice P, Lyautery J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. *Br J Haematol*. 1994;86(4):774–779.
- Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol*. 2005;58(9):882–893.
- Swets JA. Measuring the accuracy of diagnostic systems. *Science*. 1988; 240(4857):1285–1293.
- Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. *Nat Med.* 2008;14(9):985–990.
- Nygaard AD, Spindler KG, Pallisgaard N, Anderson RF, Jakobsen A. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol Rep. 2014;31:969–974.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal

Dovepress

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.